LCN2 and acute kidney injury: The composite biomarker [TIMP-2]⋅[IGFBP7] demonstrated the ability to predict AKI in large and diverse cohorts of critically ill patients in the Sapphire, Opal, and Topaz studies and better diagnostic accuracy than that of NGAL and L-FABP [23–25].